Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

Next Previous
X
Search
Trial Profile

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TPI 287 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Cortice Bioscience

    • Most Recent Events

    • 27 Jan 2016 Status changed from recruiting to discontinued due to lack of clinical benefit in the 17 subjects enrolled in the trial, according to ClinicalTrials.gov record.
    • 20 Nov 2015 Results published in a Cortice Biosciences media release.
    • 09 Nov 2015 Results from this trial will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day according to a Cortice Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top